Axim Biotechnologies Inc. released its latest results, reporting a notable shift in its financial performance. The company, known for developing diagnostic healthcare solutions, experienced a significant change in its revenue streams following the acquisition of Sapphire Biotech, Inc. Actual revenue figures showed a substantial increase compared to the previous period, largely attributed to the integration of Sapphire's operations. In terms of profitability, Axim reported a variation in net income, reflecting the impact of the recent business expansion. The company's earnings per share also experienced a notable change, indicative of its evolving market position post-acquisition. The acquisition of Sapphire Biotech, Inc. in March 2020 marked a strategic shift in Axim's business operations, with Sapphire now operating as a wholly owned subsidiary. This acquisition has been pivotal in consolidating Axim's financial reporting, signaling a significant development in its operational scope and market reach.